A股異動 | 衞光生物(002880.SZ)高開超8% 實控人將變更為國藥集團
格隆匯6月5日丨衞光生物(002880.SZ)高開超8%,報36.5元,總市值82億元。該公司上週五公佈,2023年6月2日,光明國資局與中國生物技術股份有限公司(簡稱“中國生物”)簽署了《合作協議》,約定光明國資局與中國生物擬設立合資公司,光明國資局持有合資公司49%股權,中國生物持有合資公司51%股權。合資公司設立後,光明國資局向合資公司無償劃轉公司79,947,000股股份,佔公司總股本的35.25%(以下簡稱“本次無償劃轉”)。本次無償劃轉將導致公司控股股東由光明國資局變更為擬設立的合資公司,中國生物成為公司的間接控股股東,公司實際控制人由光明國資局變更為中國醫藥集團有限公司(簡稱“國藥集團”)。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.